FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174992356> ?p ?o ?g. }

• W3174992356 abstract "Objective: To determine the number of cataplexy-free days/week experienced by participants treated with sodium oxybate (SXB) in a placebo-controlled, randomized withdrawal study in children and adolescents with narcolepsy with cataplexy. Background: Cataplexy resolves in some patients with narcolepsy when treated with SXB. Design/Methods: SXB-naive participants were titrated to an optimal dose of SXB and then entered a stable-dose period (SD) for 2 weeks; participants already taking SXB entered SD on their usual dose of SXB for 3 weeks. After a 2-week, placebo-controlled, double-blind, randomized withdrawal period (DB), participants entered an open-label safety period (OL) for a total duration of ≤1 year. Cataplexy-free days/week were calculated from daily participant diaries. Results: Of 106 participants, 74 (69.8%) were SXB naive and 32 (30.2%) were taking SXB at enrollment. In SXB-naive participants, median (Q1, Q3) cataplexy-free days/week increased during titration: week 1 (0.0 [0.0, 2.0]), week 2 (1.0 [0.0, 3.0]), and last 7 days (4.0 [1.0, 6.0]); n=71. Sixty-seven SXB-naive participants entered SD. During the last 14 days of SD, cataplexy-free days/week remained stable and were similar in participants who were SXB naive or taking SXB at study entry: 4.3 (1.0, 5.8), n=66, and 4.8 (0.8, 6.5); n=32, respectively. During the last week of DB, cataplexy-free days/week decreased to 0.0 (0.0, 2.7) in participants randomized to placebo (n=32) but remained stable at 4.0 (1.0, 6.0) in participants continuing SXB (n=31). During the last week of observation for each participant in the OL period, median cataplexy-free days/week was 5.0, in both participants who were SXB naive (n=63) and participants taking SXB at study entry (n=32). Common adverse events (>10%) in the safety population (n=104) were enuresis, nausea, vomiting, headache, and decreased weight. Conclusions: SXB treatment increased cataplexy-free days/week in children/adolescents with narcolepsy with cataplexy. The safety profile was consistent with previous adult and pediatric narcolepsy studies. Disclosure: Dr. Mignot has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr Mignot has consulted for Novo Nordisk and Reset Pharmaceuticals, and is on the speakers' bureau for Vox Media.. Dr. Mignot has received research support from Dr. Mignot has received research support from Jazz Pharmaceuticals, Merck, and Glaxo Smith Kline (GSK). Dr. Rosen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Rosen has been a consultant for Jazz Pharmaceuticals, Advance-Medical and Natus Medical.. Dr. Rosen has received research support from Has received research funding from Jazz Pharmaceuticals and Flamel Technologies and acknowledges the following support: “In Cleveland, this publication was made possible by the Clinical and Translational Science Collaborative of Cleveland, 4UL1TR000439 fr. Dr. Menno has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals. Dr. Menno has received compensation for serving on the Board of Directors of Full-time employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc.. Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals. Dr. Wang has received compensation for serving on the Board of Directors of Full-time employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc.. Dr. Profant has received compensation for serving on the Board of Directors of Full-time employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc.. Dr. Dauvilliers has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bioprojet, Flamel Technologies S.A. (now Avadel Pharmaceuticals plc), Harmony Biosciences, LLC, Idorsia Pharmaceuticals Ltd., Jazz Pharmaceuticals, Takeda Pharmaceutical Co. Ltd., Theranexus, and UCB Pharma." @default.
• W3174992356 created "2021-07-05" @default.
• W3174992356 creator A5008480675 @default.
• W3174992356 creator A5030033537 @default.
• W3174992356 creator A5059058335 @default.
• W3174992356 creator A5073040042 @default.
• W3174992356 creator A5089333547 @default.
• W3174992356 creator A5091052817 @default.
• W3174992356 date "2020-04-14" @default.
• W3174992356 modified "2023-09-23" @default.
• W3174992356 title "Cataplexy-Free Days With Sodium Oxybate Treatment in Children/Adolescents With Narcolepsy With Cataplexy (1211)" @default.
• W3174992356 hasPublicationYear "2020" @default.
• W3174992356 type Work @default.
• W3174992356 sameAs 3174992356 @default.
• W3174992356 citedByCount "0" @default.
• W3174992356 crossrefType "journal-article" @default.
• W3174992356 hasAuthorship W3174992356A5008480675 @default.
• W3174992356 hasAuthorship W3174992356A5030033537 @default.
• W3174992356 hasAuthorship W3174992356A5059058335 @default.
• W3174992356 hasAuthorship W3174992356A5073040042 @default.
• W3174992356 hasAuthorship W3174992356A5089333547 @default.
• W3174992356 hasAuthorship W3174992356A5091052817 @default.
• W3174992356 hasConcept C118552586 @default.
• W3174992356 hasConcept C126322002 @default.
• W3174992356 hasConcept C142724271 @default.
• W3174992356 hasConcept C15744967 @default.
• W3174992356 hasConcept C168563851 @default.
• W3174992356 hasConcept C204787440 @default.
• W3174992356 hasConcept C27081682 @default.
• W3174992356 hasConcept C2779494582 @default.
• W3174992356 hasConcept C2780163352 @default.
• W3174992356 hasConcept C2780714222 @default.
• W3174992356 hasConcept C42219234 @default.
• W3174992356 hasConcept C71924100 @default.
• W3174992356 hasConceptScore W3174992356C118552586 @default.
• W3174992356 hasConceptScore W3174992356C126322002 @default.
• W3174992356 hasConceptScore W3174992356C142724271 @default.
• W3174992356 hasConceptScore W3174992356C15744967 @default.
• W3174992356 hasConceptScore W3174992356C168563851 @default.
• W3174992356 hasConceptScore W3174992356C204787440 @default.
• W3174992356 hasConceptScore W3174992356C27081682 @default.
• W3174992356 hasConceptScore W3174992356C2779494582 @default.
• W3174992356 hasConceptScore W3174992356C2780163352 @default.
• W3174992356 hasConceptScore W3174992356C2780714222 @default.
• W3174992356 hasConceptScore W3174992356C42219234 @default.
• W3174992356 hasConceptScore W3174992356C71924100 @default.
• W3174992356 hasOpenAccess W3174992356 @default.
• W3174992356 hasRelatedWork W2801706337 @default.
• W3174992356 hasRelatedWork W2802731780 @default.
• W3174992356 hasRelatedWork W2803651213 @default.
• W3174992356 hasRelatedWork W2803956198 @default.
• W3174992356 hasRelatedWork W2804412694 @default.
• W3174992356 hasRelatedWork W2808054523 @default.
• W3174992356 hasRelatedWork W2811297374 @default.
• W3174992356 hasRelatedWork W2885049414 @default.
• W3174992356 hasRelatedWork W2893281143 @default.
• W3174992356 hasRelatedWork W2902379087 @default.
• W3174992356 hasRelatedWork W2962303456 @default.
• W3174992356 hasRelatedWork W3019112891 @default.
• W3174992356 hasRelatedWork W3043068731 @default.
• W3174992356 hasRelatedWork W3106779577 @default.
• W3174992356 hasRelatedWork W3159402725 @default.
• W3174992356 hasRelatedWork W3183081226 @default.
• W3174992356 hasRelatedWork W3185129165 @default.
• W3174992356 hasRelatedWork W3189627156 @default.
• W3174992356 hasRelatedWork W3198538026 @default.
• W3174992356 hasRelatedWork W3199451569 @default.
• W3174992356 hasVolume "94" @default.
• W3174992356 isParatext "false" @default.
• W3174992356 isRetracted "false" @default.
• W3174992356 magId "3174992356" @default.
• W3174992356 workType "article" @default.